

THURSDAY 13th MAY 2021 – DAY 1

Start	Finish	Stream 1	Start	Finish	Stream 2
08:25	08:55	Live Poster Presentations - Session 1			
09:00	09:05	Welcome from Mr Philip Rolland and Mr Jonathan Frost			
09:05	09:15	Welcome from the President of the BGCS Professor Sudha Sundar			
09:15	11:00	Session 1A Ovarian cancer <i>This will be an interactive session to explore current advances in the surgical and systemic treatment of advanced ovarian cancer, focussing on the integration of surgical effort and novel targeted therapeutics. Multidisciplinary discussions will address patient-oriented metrics from survival to quality of life and survivorship aspects</i>	09:15	11:00	Session 1B Complex Brachytherapy <i>Dose escalation in image guided brachytherapy has improved local control in cervical cancer and has been widely adopted. We review the use of HDR brachytherapy in more complex situations, primary vaginal cancer, cancer of vagina/vulva and cancer in a cervical stump. Brachytherapy is compared to SBRT and we examine radiographer challenges and patient experience.</i>
		Co-Chairs: Professor Christina Fotopoulou & Professor Jonathan Ledermann			Co-Chairs: Dr Audrey Cook & Dr Alexandra Taylor
09:15	09:20	Introduction	09:15	09:20	Introduction
09:20	09:35	Fragility Score for preoperative patient selection	09:20	09:25	Voting questions
09:35	09:50	Value of surgery in recurrent ovarian cancer	09:25	09:40	Presentation and discussion of Case 1 (lower vaginal/vulval carcinoma)
09:50	10:05	How to set up a HIPEC service	09:40	09:50	Radiographer challenges and patient experience
10:05	10:20	Are the results of the CA125 follow up trial (MRC, OV05/ EORTC 55955) still relevant?	09:50	10:05	Presentation and discussion of case 2 (primary vaginal cancer)
10:20	10:35	Follow up of patients on maintenance therapy	10:05	10:20	Presentation and discussion of case 3 (carcinoma in cervical stump)
			10:20	10:30	Brachy v SBRT
10:35	11:00	Panel Discussion / Live Q&A	10:30	10:55	Panel Discussion / Live Q&A
			10:55	11:00	Final Vote and summing up
11:00	11:20	Poster Viewing / Break			

11:20	13:20	Session 2A		11:20	12:15	Session 2B		
		Endometrial cancer <i>Prof Naveena Singh and Dr Stephanie de Boer describe the molecular classification of endometrial cancer and its implications for clinical care; Prof Emma Crosbie and Dr Cheryl Fitzgerald discuss fertility-sparing management for endometrial cancer; and Mr James Bristol explains the good, the bad and the ugly of hormone cancer therapies.</i> Co-Chairs: Professor Emma Crosbie & Dr Jo Morrison				Patient testimonies / Charities <i>Third sector support is all about collaboration! Not just collaborating with and supporting our patients, our charity colleagues support us the clinicians. This is the theme of our charities session this year. We will showcase collaborative charity projects and hear the latest update from all our third sector partners.</i> Co-Chairs: Ms Hilary Maxwell & Dr Tracie Miles		
11:20	11:22	Welcome and Introduction	Professor Emma Crosbie	11:20	11:22	Introduction to session and updates from Charities	Ms Hilary Maxwell & Dr Tracie Miles	
11:22	11:37	Molecular classification: towards personalised care in endometrial cancer	Professor Naveena Singh	11:22	11:40	Pan gynae charities project on Digital Inclusion from Macmillan Cancer		
11:37	11:57	Looking back at PORTEC3, forward to PORTEC4 and somewhere over the RAINBO	Dr Stephanie de Boer	11:40	11:45	Eve appeal Update		
11:57	12:07	Q&A with Professor Naveena Singh and Dr Stephanie de Boer		11:45	11:50	Go Girls Update		
12:09	12:29	The conservative management of endometrial cancer	Professor Emma Crosbie	11:50	12:00	Jo's Trust Update		
12:29	12:44	Fertility after endometrial cancer	Dr Cheryl Fitzgerald	12:00	12:05	Target Ovarian Update		
12:44	12:54	Q&A with Professor Emma Crosbie and Dr Cheryl Fitzgerald		12:05	12:10	Ovacom Update		
12:55	13:10	Tamoxifen and the LNG-IUS: Friend or foe? The Breast Surgeon's perspective	Mr James Bristol	12:10	12:15	Ovarian Cancer Action Update		
13:10	13:15	Q&A with Mr James Bristol						
13:20	13:35	Live Poster Presentations - Session 2						
13:35	14:20	Personalising treatment beyond BCRA - Understanding genomic testing in advanced ovarian cancer. <i>MSD and AstraZeneca promotional educational industry symposia, for UK HCPs only</i>						
13:35	13:37	Welcome & Introductions						Professor Sudha Sundar
13:37	13:50	Expanding genomic testing beyond BRCAm						Dr Susana Banerjee
13:50	14:10	Genomic testing in practice						Professor Sudha Sundar Dr Susana Banerjee Ms Laura Appadu
14:10	14:20	Q&A Session						All
14:20	14:35	Live Poster Presentations - Session 3						
14:35	15:20	Session 3A		14:35	15:20	Session 3B		
		BGCS supported COVID-19 Projects <i>The COVID-19 pandemic significantly impacted our ability to deliver gynaecology oncology services. This session will provide an overview of 3 research projects that were supported with funding from the BGCS COVID Research Grants scheme in 2020, OvarianPsych, CovidSurg and UKCOGS.</i> Co-Chairs: Mr Nicholas Wood & Mr James Dilley				Hormone replacement therapy after gynaecological cancer treatment <i>Advances in the treatment of gynaecological malignancy has resulted in prolonged survival with greater demand from survivors to manage quality of life. Provision of HRT to women following cancer treatment presents a challenge to many healthcare professionals necessitating interpretation of the sparse evidence base, consideration of primary tumour biology, assessment and explanation of associated risk as well as knowledge of available preparations and routes of administration. This whistle-stop tour of HRT aims to outline the evidence, provide a structured approach to assessment, outline prescription principles as well as consider the wider morbidity of menopause and non-hormonal management options.</i> Co-Chairs: Dr Rachel O'Donnell & Dr Andrew Phillips		

14:35	14:40	Welcome and introduction	Mr Nick Wood & Mr James Dilley	14:35	14:38	Welcome and Introductions	Dr Andrew Phillips
14:40	14:50	Psychological impact of the COVID-19 crisis on women undergoing treatment for ovarian cancer- a longitudinal mixed methods study.	Mr Ketankumar B Gajjar	14:38	14:43	Why do we need to talk about HRT	Dr Rachel O'Donnell
14:50	15:00	The Impact of the COVID-19 pandemic on gynaecological cancer surgery- Update from the COVIDSurg-Cancer: An International Multi-Centre Cohort Study	Dr Elaine Leung	14:43	15:18	HRT after gynaecological malignancy; evidence, principles and case study	Dr Kathryn Clement
15:00	15:10	United Kingdom COVID and Gynaecological Cancer Study	Professor Ranjit Manchanda	15:18	15:20	Panel Discussion / Live Q&A	All
15:10	15:20	Panel Discussion / Live Q&A	All				
15:20	15:35	Poster Viewing / Break					
15:35	16:55	Session 4A		15:35	16:55	Session 4B	
		<p>NHS Cancer Work Programme Updates & Oral Abstracts <i>This session summarises the latest data from the NCRAS Ovarian Cancer Audit Feasibility Pilot and the NHS care plan 2021, as well as four pre-offered abstracts, to help us reflect and set out our commitments to improve cancer outcomes and services in the UK.</i></p>				<p>Genomic Testing Updates in Gynaecological Cancer <i>Following on from the success of the 100k genomes project , the NHS is now starting to offer AND deliver genomic testing in both rare diseases and cancer tumour sites. During this session we will give you an update on the current testing offers for our gynae cancer describing the MAINSTREAMING approach and encourage questions from yourselves to our multi- disciplinary speakers.</i></p>	
		Co-Chairs: Professor Sadaf Ghaem-Maghani & Dr Elaine Leung				Co-Chairs: Dr Tracie Miles & Ms Melanie Watson	
15:35	15:40	Overview summary	Professor Sadaf Ghaem-Maghani	15:35	15:37	Introduction to Session	Dr Tracie Miles & Ms Melanie Watson
15:40	15:55	NHS cancer plan 2021	Mr Rob Gornall	15:37	15:57	BRCA and HRD testing update	Professor Rachel Butler
15:55	16:10	NCRAS Ovary – the next steps	Mr Andy Nordin	15:59	16:09	Patient consent and research offer update (mainstreaming)	Ms Amanda Pichini
16:10	16:23	Panel Discussion / Live Q&A	All	16:11	16:21	Lynch Syndrome and Gynaecology Cancer testing Update	Dr Neil Ryan
16:23	16:31	Cancer alliances which have high rates of surgery for advanced ovarian cancer demonstrate improved overall survival	Dr Katie Baxter	16:23	16:33	Lynch Syndrome Laboratory Update	Dr Raji Ganesan
16:31	16:39	ACS NSQIP - Personalised Risk Prediction Tool for Postoperative Complications in Gynaecology Surgery?	Dr Lusine Sevinyan				
16:39	16:47	Technique for inguino-femoral lymph node dissection in vulvar cancer: An international survey	Dr Sadie Jones	16:33	16:55	Panel Discussion / Live Q&A	All
16:47	16:55	Skin capillary rarefaction occurs during treatment for high grade serous ovarian cancer and is a potential biomarker of Bevacizumab treatment	Dr Gemma Cass				
17:00	17:05	Presentation CREST Award to Professor Emma Crosbie: Professor Richard Shaw					
17:05		Close					

FRIDAY 14 th MAY 2021 – DAY 2									
Start	Finish	Stream 1			Start	Finish	Stream 2		
08:25	08:55	Live Poster Presentations - Session 4							
09:00	10:00	Session 5A			09:00	10:35	Session 5B		
		<p>NCRI Gynaecological Group updates The National Cancer Research Institute (NCRI) Gynaecological Group presents updates of the latest trial data and on going trials from the Ovarian, Endometrial, Cervix and Vulval Cancer subgroups, and provides details for new investigators on how to get involved in clinical research.</p> <p>Co-Chairs: Dr Shibani Nicum</p>					<p>Providing a Service This session will cover:-</p> <ul style="list-style-type: none"> How to work effectively with your anaesthetist in relation to the obese patient. The importance of hysteroscopy in diagnosis of endometrial cancer and the results of a national audit on pain perception experienced during OPD hysteroscopy. A light-hearted review of some of the challenges experienced during a very difficult year. <p>Co-Chairs: Mr Bruce Ramsay & Mr Partha Sengupta</p>		
09:00	09:10	Welcome and Introduction- NCRI strategy and speakers	Dr Shibani Nicum		09:00	09:05	Introduction to session	Mr Bruce Ramsay	
09:10	09:25	Update from Ovarian Cancer Workstream	Dr Rebecca Bowen		09:05	09:30	Working with your anaesthetist	Dr Owen Bodycombe	
09:25	09:40	Update from the Endometrial Workstream	Professor Emma Crosbie		09:30	09:40	Q&A with Dr Owen Bodycombe		
09:40	09:50	Update from the Cervical Workstream	Dr Emma Hudson						
09:50	10:00	Panel Discussion / Live Q&A	All		09:40	10:10	Hysteroscopy: Making the cancer diagnosis	Professor Justin Clark	
10:05	10:35	Session 6			10:10	10:20	Q&A with Professor Justin Clark		
		<p>Vulval Cancer This presentation will give you an update on the GROINSS-V studies in vulvar cancer including the GROINSS-V III study, which started recruiting in 2021. GROINSS-V II investigated whether inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy in patients with a metastatic sentinel node.</p> <p>Chair: Ms Claire Newton</p>							
10:05	10:25	GROINNS V-II/III	Dr Maaïke Oonk		10:20	10:35	The day I was asked to clean the toilet	Ms Hilary Maxwell	
10:35	10:55	Break/Posters							

10:55	11:45	Session 7A		10:55	12:30	Session 7B							
		MDT Analysis Session MDTs – time for a change and notes from a pathologist. <i>Ben Lamb will discuss his research on the cancer MDT particularly with respect to communication and the implications for patient safety. Raji Ganesan will highlight the changes in the fifth edition of the WHO classification of tumours of the female genital tract and include case studies.</i>				Medical Oncology We review the medical management of low grade serous ovarian cancers and the role of endocrine therapies in gynaecological cancers. We also discuss the management of immunotherapy toxicities as these treatments have a role in some endometrial cancers and in many clinical trials.							
		Co-Chairs: Mr Timothy Duncan & Mr Barnaby Rufford				Co-Chairs: Dr Rebecca Bowen & Dr Anna Olsson-Brown							
10:55	10:57	Welcome to session & introduction	Mr Timothy Duncan	10:55	11:00	Introduction to session	Dr Rebecca Bowen						
10:57	11:15	MDTs - time for a change?	Mr Ben Lamb	11:00	11:20	Medical management of low grade serous ovarian cancer	Dr Susana Banerjee						
11:17	11:40	Notes from a pathologist	Dr Raji Ganesan										
11:40	11:45	Panel Q&A	All										
11:50	12:30	Session 8A		11:40	11:55	12:15	Immunotherapy toxicity						
		Guidelines <i>Prof Emma Crosbie and Dr Melanie Powell will review surgical and non-surgical aspects of the recently published European Guidelines for management of endometrial cancer and their implications for practice in the UK and forthcoming BGCS guidelines.</i>						11:55	12:15	Immunotherapy toxicity	Ms Nikki Hunter		
		Co-Chairs: Dr Alexandra Taylor & Dr Jo Morrison											
		11:50	11:58									BGCS Guidelines Subgroup Introduction	Dr Alexandra Taylor
		11:58	12:10									ESGO-ESTRO endometrial guidelines - surgical aspects	Professor Emma Crosbie
		12:10	12:22									ESGO-ESTRO endometrial guidelines - oncology aspects	Dr Melanie Powell
12:22	12:30	Panel Discussion / Live Q&A	All										
12:30	12:45	Posters/Lunch											
12:45	13:30	Industry Symposia - GSK - BRCA and beyond: a new era in first-line maintenance treatment of advanced ovarian cancer											
12:45	13:00	Evaluating the first-line maintenance treatment options in AOC - who should get what?					Dr Susana Banerjee						
13:00	13:15	Understanding PRIMA: from clinical trial to clinical practice					Dr Jonathan Krell						
13:15	13:25	A clinical case study with a patient-focused approach to monitoring					Dr Rowan Miller						
13:25	13:30	Panel discussion and audience Q&A											
13:30	13:40	Break											

13:40	15:00	Session 9A		13:40	15:00	Session 9B			
		<p>Succeeding with surgical trials This session focuses on design and evidence base in surgical trials and explores challenges faced in developing surgical trials. We conclude by discussing the experience of running the LACC trial in cervical cancer. There will be an opportunity for an interactive Q&A with the panel.</p> <p>Co-Chairs: Professor Sean Kehoe & Mr Stephen Dobbs</p>				<p>Nursing Forum Part 1 This year's Nursing Conference Agenda explores a wide variety of issues in a very challenging year. Aimed at gynae-oncology clinical nurse specialists, allied health professionals and gynaecology ward staff, the team aim to look at the wider challenges of COVID 19 on clinical staff and key areas of clinical practice.</p> <p>Co-Chairs: Ms Hilary Maxwell & Dr Tracie Miles</p>			
13:40	13:45	Welcome & Introduction	Professor Sean Kehoe	13:40	14:00	Welcome & Introductions		Ms Hilary Maxwell	
13:45	14:00	Evidence based surgical practice	Professor Jane Blazeby	14:00	14:20	Radiotherapy: Managing Consequences for Patients - the Short & Long Term Impacts		Dr Rachel Wilkinson	
14:01	14:16	Design considerations of surgical trials	Professor Allan Hackshaw	14:20	14:30	Q&A with Dr Rachel Wilkinson			
14:17	14:32	The Challenges of Surgical Trials	Professor Sean Kehoe	14:45	15:00	CV19: Fallout & Recovery		Dr Melissa Girling	
14:33	14:48	The LACC Study: Experiences from a Surgical Trial	Professor Pedro Ramirez	15:00	15:02	Polling Questions		Ms Hilary Maxwell	
14:48	15:00	Panel Discussion / Live Q&A	All						
15:00	15:15	Break							
15:15	17:05	Session 10A		15:15	16:50	Session 10B			
		<p>The surgical management of cervical cancer During this session we will explore the latest evidence and guidance for the approach to cervical cancer surgery. This will include an analysis of the NCRAS review of outcomes, the LACC trial, the SUCCOR study as well as the ongoing RACC and ROCC trials and the latest NICE Health Technology Assessment.</p> <p>Co-Chairs: Mr Thomas Ind & Mr Jonathan Frost</p>				<p>Nursing Forum Part 2</p> <p>Co-Chairs: Ms Hilary Maxwell & Dr Tracie Miles</p>			
15:15	15:20	Introduction to session	Mr Thomas Ind & Mr Jonathan Frost	15:15	15:30	Q&A with Dr Melissa Girling			
15:20	15:43	NCRAS cervical cancer radical hysterectomy analysis and the NICE Health Technology Assessment	Mr Andy Nordin	15:30	15:50	Transitioning to End of Life: Management of Patients & Their Families		Dr Paul Barker	
15:45	16:08	Open vs MIS approach for radical hysterectomy and radical hysterectomy: Where are we now?	Professor Pedro Ramirez	15:50	16:00	Q&A with Dr Paul Barker			
16:10	16:33	Open vs MIS approach for radical hysterectomy and radical hysterectomy: Is there still a role for MIS?	Dr Luis Chiva	16:00	16:20	Managing Cancer Patients in the Digital Age - New Ways of Working & the Digital Recovery Agenda		Ms Abigail Orchard	
16:35	16:40	The RACC trial	Dr Henrik Falconer	16:20	16:30	Q&A with Abigail Orchard			
16:40	16:45	The ROCC trial	Dr Mario Leitao	16:35	16:40	Closing Remarks		Ms Hilary Maxwell	
16:45	17:05	Some 1b1 cancers are best treated by MIS: Panel Discussion / Live Q&A	All						
17:05	17:15	Prizes and Close - Professor Sudha Sundar, President of the BGCS							

The BGCS 2021 conference is supported by the companies below. They have organised their industry symposia but have had no input into the agenda or selection of topics or speakers.

Diamond



Platinum

